XenaCare Holdings Announces Updates to Cobroxin Distribution and National Advertising Campaign

XenaCare Holdings Has Announced that Cobroxin Has Begun Selling in Mass Food and Drug Retail Chains in the Northeast, Southeast, Middle Atlantic and Midwest Regions; Additionally, the Company Has Committed to a $7 Million National Advertising Campaign and Direct Response Marketing Campaign

{"s" : "nphc.ob,xcho.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: XenaCare Holdings On Thursday February 11, 2010, 1:17 pm
DELRAY BEACH, Fla.--(BUSINESS WIRE)--XenaCare Holdings, Inc. (OTCBB:XCHO - News), a company specializing in the marketing and retail distribution of consumer healthcare products, announced today that it has begun distributing and selling Cobroxin through mass food and drug retail chains in the Northeast, Southeast, Middle Atlantic and Midwest regions. The Company has also announced that sales of Cobroxin have exceeded projections for the first 45 days of 2010.

“Sales of Cobroxin have already exceeded our projections for the beginning of this year,” explained Frank Rizzo, President and CEO of XenaCare Holdings. “Reorder rates from our customers have been very strong at all levels of our distribution grid and have required us to reorder inventory four times from Nutra Pharma since placing our initial order for the product,” he added.

To support sales of Cobroxin, XenaCare has committed to a $4 million print advertising campaign for the first 12-months. This campaign includes advertisements in Health, Prevention, Self, Soap Opera Digest, Working Mother, Woman’s Day, Shape, Martha Stewart, Redbook, Ladies Home Journal, Allure, Wired, Web M.D. and Arthritis Today magazines.

In addition to its national print campaign, the Company has contracted with the Home Shopping Group to organize direct response television commercials set to begin airing in March 2010. Additionally, the Company has committed to a $3 million television broadcast campaign.

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. The drug is currently available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:


All Natural
Non-Addictive
Non-Narcotic
Non-Opiate
Long Lasting

XenaCare Holdings was granted a license by Nutra Pharma Corporation (OTCBB:NPHC - News) to market and distribute Cobroxin within the United States.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin, for the treatment of moderate to severe (Stage 2) chronic pain, the Company’s clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. In addition, the company offers formulations for the lifestyle performance market, which consists of a sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet as well as pharmacies. The company was founded in 2001 and is based in Delray Beach, Florida.

http://www.XenaCareHoldings.com

http://www.Cobroxin.com

Cautionary Note Concerning Forward Looking Statements

Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans for specific advertising and marketing campaigns supporting Cobroxin are forward looking statement and subject to change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.

What always happens after a dip? Why of course, a bounce back. So let the panic sellers sell at the bottom, and watch the buyers come in and buy it back up. If it dips tomorrow, I will be there to buy shares to increase my position. An opportunity to pick up shares at a lower price, priceless....

Uptick! Ask is at 0.125 and bid is at 0.124 now.

That means most of the sellers are out, so there are less resistance that we have to break through. I think the last two days gave sellers plenty of opportunity to get out. And those who bought in are holding out for much bigger gains. I know I am :)

They are not getting my shares for cheap.

I am glad I bought shares today. The charts say this uptrend is just starting and the pps is going much higher. Just look at the massive volume these last two days; it correlates with the pps surge.